A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol
in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood
and cerebrospinal fluid will be measured.